Ann Thorac Surg 2002;73:S366
© 2002 The Society of Thoracic Surgeons
SUPPLEMENT: OUTCOMES 2001: SCIENTIFIC ABSTRACTS
S100ß in neonates and infants with congenital heart disease
P. Bokesch, MDa,
M. Cavaglia, MDa,
E. Appachi, MDa,
E. Mossad, MDa,
J. Tome, MDa,
R. Mee, MDa
a Departments of Cardiothoracic Anesthesia and Pediatrics, Cleveland Clinic, Cleveland, Ohio, USA
Introduction. The brain-derived protein S100ß is a serum marker for brain damage. Adults with increased serum levels of S100ß (>0.5 µg/L) after cardiac surgery have strokes and adverse neurological outcomes. The purpose of this study was to measure S100ß in neonates and infants with congenital heart defects (CHD) before and after surgery.
Methods. One hundred nine patients (age 2 days to 1 year) who underwent open-heart surgery using cardiopulmonary bypass were studied. Serum collected before incision and 24 hours after surgery was analyzed for S100ß protein using a monoclonal two-site immunoluminometric assay (LIA-MAT Sangtec 100).
Results. Group I: 32 neonates 7.6 ± 0.8 days old with hypoplastic left heart syndrome (HLHS), stage I Norwood: group II: 28 neonates 10.7 ± 1.7 days old with TGA, arterial switch; group III: 10 infants 6.5 ± 3 months old for TOF repair; group IV: 21 infants 5.8 ± 2 months old for bidirectional Glenn shunt; group V: 18 infants 3.6 ± 2 months old for VSD or CAVC closure. (Table 1)
Conclusions. Neonates with CHD have significantly elevated S100ß before surgery. Increased pulmonary blood flow is associated with higher S100ß levels preoperatively than cyanosis in infants. S100ß levels in normal neonates and infants without CHD are being determined in our laboratory.
